Tag: MIRA

NIGMS continues to support a broad range of scientific topics and investigators within its research portfolio, including support for investigator-initiated research project grants (RPGs) at institutions throughout the country. As part of its commitment to transparency, NIGMS examines and publishes data on annual trends reflected in its RPG portfolio. In this post, we review and describe investigator-level trends associated with competing R01/R01-equivalent RPGs including those in the Institute’s R35 Maximizing Investigators’ Research Award (MIRA) program.

NIGMS continues to support a wide range of topics and investigators, maintaining a broad biomedical research portfolio. In Fiscal Year (FY) 2022, NIGMS received a congressional appropriation of $3,092,373,000. Consistent with the Institute’s mission, a large portion of these funds support investigator-initiated research project grants (RPGs) at institutions throughout the country. As part of its commitment to transparency, NIGMS publishes data on annual trends in its grant portfolios. In this post, we describe investigator-level trends for RPGs and review the trends associated with competing RPGs as well as those in the Institute’s Maximizing Investigators’ Research Award (MIRA) program.

NIGMS Investigator-Level Trends for Research Grants

At NIGMS, we focus on supporting a broad group of investigators. As a result, we monitor two statistics that describe our investigator pool: the cumulative investigator rate and the number of funded early stage investigators (ESIs). The number of newly funded ESIs has notably increased over recent years, and continued support for ESIs is integral to the success of the biomedical research enterprise and is a priority for the Institute. Figure 1 illustrates the number of ESIs who received their first competing NIGMS R01-equivalent grants each year between FY 2013 and FY 2022. In FY 2022, NIGMS awarded R01-equivalent grants to 319 ESIs in total: 31 investigators received R01 awards, 268 investigators received R35 (MIRA) awards, and 20 investigators received NIH Director’s New Innovator Awards (DP2s). These data include DP2s (four awards) administered by NIGMS on behalf of the NIH Office of the Director. The number of funded ESI MIRAs in FY 2022 was the largest to date, and more than four times larger than in the program’s first year. Overall, the number of funded ESIs has risen almost every year since FY 2013, with the slight decrease in the number of awards between FY 2017 and FY 2018 due in part to the introduction of the MIRA program in FY 2016 and a temporary reduction in the built-up ESI applicant pool as more ESIs received funding.

NIGMS maintains a diverse biomedical research portfolio, supporting a wide range of topics and investigators. In Fiscal Year (FY) 2021, NIGMS received a congressional appropriation of $2,991,417,000. As part of the Consolidated Appropriations Act, 2022, this budget increased by 3.4% to $3,092,373,000 for FY 2022. The majority of these funds support research project grants (RPGs) at research institutions throughout the country. In alignment with its commitment to transparency, NIGMS publishes data on annual trends in its grants portfolio. In this post, we first describe investigator-level trends for RPGs, then review the trends associated with competing RPGs, and lastly examine trends in the Institute’s Maximizing Investigators’ Research Award (MIRA) program.